GFLAS Life Sciences utilizes CRISPR-CasN technology to develop genome-edited crops, such as vitamin D3 tomatoes, which enhance nutritional content. The company addresses the need for improved food quality and health benefits in agricultural products through precise genetic modifications.
Funding
$2.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current agricultural practices often result in crops with limited nutritional value, necessitating supplementation or dietary changes to meet recommended daily intakes of essential nutrients. Traditional breeding methods are time-consuming and may not efficiently address specific nutritional deficiencies in staple foods.
Solution
GFLAS Life Sciences leverages CRISPR-CasN genome editing technology to develop crops with enhanced nutritional profiles, addressing the growing demand for healthier and more nutritious food sources. Their technology enables precise modification of plant genomes to increase the levels of specific vitamins and nutrients, such as vitamin D3 in tomatoes. This approach offers a faster and more targeted alternative to conventional breeding, allowing for the creation of crops with improved health benefits and reduced reliance on external supplementation. The company is also developing a plant-based bio-pharmaceutical production system using glyco-engineering to enhance ADCC (Antibody-Dependent Cellular Cytotoxicity) in bio-therapeutics.
Target Audience
The primary target audience includes agricultural companies, food producers, and consumers seeking nutritionally enhanced food options, as well as pharmaceutical companies looking for innovative bio-manufacturing platforms.
Features
- CRISPR-CasN genome editing for precise and targeted crop modification
- Development of vitamin-enriched crops, including vitamin D3 tomatoes
- Plant-based bio-pharmaceutical production platform using glyco-engineering
- ADCC enhancement technology for improved bio-therapeutic efficacy
- CRISPR PLUS® gfCas12a® technology
- Cancerase CRISPR anti-cancer drug platform targeting cancer-specific mutations
- Non-GMO editing capabilities